GeoPolitics Pulse

The Heartbeat of World events

Ipsen’s Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in …

by ·

PARIS, FRANCE, 23 September, 2024 Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the European Commission has approved Kayfanda® (odevixibat) …Read More

Related posts:

  1. Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy …
  2. Mirum Pharmaceuticals’ LIVMARLI Approved in the European Union for Patients with PFIC
  3. Mirum Pharmaceuticals’ LIVMARLI Approved in the European Union for Patients with PFIC
  4. Ipsen’s Iqirvo® (elafibranor) approved in the European Union as first new treatment for …
  5. Dupixent® (dupilumab) Approved in the European Union as the – GlobeNewswire